Did CVDs recover post COVID-19 ?

By Staff Writer

March 31, 2023

The World Health Organization expressed concern about the disruption of essential health services for chronic disease management due to the COVID-19 pandemic. A study done in Indonesia’s Malang district, showed concerns regarding restrictions on movement and access to health services for patients with chronic conditions, such as those at high risk for cardiovascular disease. However, fears about disruptions to the supply of essential medicines were largely unfounded, as primary health centers and private suppliers had supplies of all cardiovascular medicines on hand.

While public facilities saw a significant drop in patient numbers and dispensing of CVD medicines, sales volumes at private pharmacies quickly picked up again and exceeded pre-pandemic levels within three months. Some patients who would normally get medicines free in the public sector may have been buying low-cost medicines from pharmacies during the pandemic. The response to ensuring continuity of medicine supply to CVD patients varied in different countries, with some promoting greater use of telemedicine.

However, effective control of CVD requires regular monitoring of a patient’s clinical condition, which may suffer if patients are unable or unwilling to visit health facilities. The risk of planning procurement orders annually or bi-annually was illustrated, as dramatic changes in demand can lead to shortages or over-supply.

In the Indonesian context, the private sector was able to pick up some of shortfall in CVD medicine provision reported by public services, including increasing its sales of INN and other affordable generic medicines. Were these studies replicated in other countries?

Reference url

Recent Posts

Trump drug price reform
Health Policy Health reform and legislation Healthcare access North America Statistical modelling and simulation 

A Systems Dynamics Approach to Lowering Drug Prices by 30–80% in the US

Rene Pretorius

💡 Can the U.S. lower drug prices by 30–80% while improving access and preserving innovation?

President Trump’s recent Executive Order lays the groundwork for bold reforms—targeting international price gaps, PBM markups, and regulatory delays.

This article applies a systems dynamics approach to identify leverage points and feedback loops driving high U.S. drug costs—and outlines concrete, policy-based strategies to reverse them.

Explore how systemic thinking can drive sustainable, scalable change in U.S. pharmaceutical pricing.

#SyenzaNews #DrugPricing #HealthcarePolicy #SystemsThinking #PharmaInnovation

EU Multiannual Financial Framework
Artificial intelligence and machine learning Europe Health Equity and Access to Care Health Policy Innovative Tech 

EFPIA Advocates for Stronger Life Sciences in EU Multiannual Financial Framework

João L. Carapinha

💡 How can the EU strengthen its pharmaceutical sector for the future?

The EFPIA has laid out critical recommendations for the next EU Multiannual Financial Framework (2028-2034), focusing on boosting funding for life sciences research, enhancing regulatory competitiveness, and improving health data infrastructure. These insights could significantly shape the future landscape of healthcare in Europe.

Dive into the full article to learn how these recommendations aim to propel innovation and increase access to medicines across Europe!

#SyenzaNews #pharmaceuticals #healthcarepolicy

NICE health technology evaluations
Europe Health economic evaluations Health Equity and Access to Care Health Policy Healthcare decision modelling Healthcare systems HTA HTA policies 

Evolving NICE Health Technology Evaluations: Enhancing Patient Perspectives and Addressing Health Inequalities

João L. Carapinha

🌟 Are you ready to embrace a new era in health technology evaluations?

Our latest article dives into the recent updates from NICE regarding the incorporation of patient perspectives and tackling health inequalities in their health technology assessments. By exploring stakeholder feedback and proposed methodologies, we uncover a shift towards more inclusive and transparent evaluations that could reshape market access and reimbursement policies in the UK healthcare system.

Don’t miss out on these vital insights that could impact your understanding of healthcare value! Read the full article [here](https://www.nice.org.uk/process/pmg36/documents/consultation-comments-and-responses).

#SyenzaNews #HealthEconomics #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.
PARTNER WITH US
schedule a meeting

SPEAK WITH US

+1 617 219 9400

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

WRITE US

inquiry2023@syenza.com

JOIN NEWSLETTER




SERVICES

QUICK LINKS

LINKEDIN
TWITTER
© 2025 Syenza™. All rights reserved.
Made with by Frogiez
schedule a meeting